Boehringer targets NASH/MASH with $2bn Ribo alliance

Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or

Trial finds Lilly’s Olumiant could treat type 1 diabetes

Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, pote

Phase 3 trial dashes Oramed's oral insulin hopes

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase

Amgen to push latecomer obesity drug into midstage testing

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2

Merck & Co to repurpose failed obesity drug for NASH

Merck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson & Johnson, into a therapy for the fatty liver disease known as NASH.

MiNA’s gene-activating tech wins an AstraZeneca alliance